Optimal drug treatment regimens for HIV depend on adherence

Journal of Theoretical Biology

Volumn 246, Issue 3, 2007, Pages 499-509

  Krakovska, O ^a   Wahl, L M ^a  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

Adherence; Drug resistance; HIV; Mathematical model; Theoretical immunology; Toxicity

Indexed keywords

ABACAVIR; AMPRENAVIR; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; RITONAVIR; STAVUDINE; ZIDOVUDINE;

DISEASE; DISEASE TREATMENT; DRUG; DRUG RESISTANCE; HALF LIFE; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNE SYSTEM; NUMERICAL MODEL; PROTEIN; TOXICITY;

ANTIBIOTIC RESISTANCE; ARTICLE; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; DRUG DOSE REGIMEN; DRUG HALF LIFE; DRUG TOXICITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MATHEMATICAL MODEL; PRIORITY JOURNAL; VIRUS LOAD;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CLINICAL PROTOCOLS; DRUG RESISTANCE, VIRAL; HALF-LIFE; HIV INFECTIONS; HIV-1; HUMANS; MODELS, IMMUNOLOGICAL; PATIENT COMPLIANCE;

HUMAN IMMUNODEFICIENCY VIRUS;

EID: 34247630656     PISSN: 00225193     EISSN: 10958541     Source Type: Journal    
DOI: 10.1016/j.jtbi.2006.12.038     Document Type: Article

References (45)

1. Ammassari A., Murri R., Pezzotti P., Trotta M.P., Ravasio L., De Longis P., Lo Caputo S., Narciso P., Pauluzzi S., Carosi G., Nappa S., Piano P., Izzo C.M., Lichtner M., Rezza G., and Monforte A. Self-reported symptoms and medication side effects influence adherence to highly active antiretroviral therapy in persons with HIV infection. J. Acquir. Immune Defic. Syndr. 5 28 (2001) 445-449
2. Arnsten J.H., Demas P.A., Farzadegan H., Grant R.W., Gourevitch M.N., Chang C.J., Buono D., Eckholdt H., Howard A.A., and Schoenbaum E.E. Antiretroviral therapy adherence and viral suppression in HIV-infected drug users: comparison of self-report and electronic monitoring. Clin. Infect. Dis. 338 8 (2001) 1417-1423
3. Bangsberg D.R., Hecht F.M., Charlebois E.D., Zolopa A.R., Holodniy M., Sheiner L., Bamberger J.D., Chesney M.A., and Moss A. Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population. AIDS 14 4 (2000) 357-366
4. Bangsberg D.R., Charlebois E.D., Grant R.M., Holodniy M., Deeks S.G., Perry S., Conroy K.N., Clark R., Guzman D., Zolopa A., and Moss A. High levels of adherence do not prevent accumulation of HIV drug resistance mutations. AIDS 17 13 (2003) 1925-1932
5. Bangsberg D.R., Moss A.R., and Deeks S.G. Paradoxes of adherence and drug resistance to HIV antiretroviral therapy. J. Antimicrob. Chemother. 53 5 (2004) 696-699
6. de Olalla G.P., Knobel H., Carmona A., Guelar A., Lopez-Colomes J.L., and Cayla J.A. Impact of adherence and highly active antiretroviral therapy on survival in HIV-infected patients. J. Acquir. Immune Defic. Syndr. 30 1 (2002) 105-110
7. DeGruttola V., Dix L., D'Aquila R., Holder D., Phillips A., Ait-Khaled M., Baxter J., Clevenbergh P., Hammer S., Harrigan R., Katzenstein D., Lanier R., Miller M., Para M., Yerly S., Zolopa A., Murray J., Patick, Aand Miller V., Castillo S., Pedneault L., and Mellors J. The relation between baseline HIV drug resistance and response to antiretroviral therapy: re-analysis of retrospective and prospective studies using a standardized data analysis plan. Antivir. Ther. 5 1 (2000) 41-48
8. Descamps, D., Flandre, P., Calvez, V., Peytavin, G., Meiffredy, V., Collin, G., Delaugerre, C., Robert-Delmas, S., Bazin, B., Aboulker, J.P., Pialoux, G., Raffi, F., Brun-Ve'zinet, Franc, O., and for the Trile'ge (Agence Nationale de Recherches sur le SIDA 072) Study Team, 2000. Mechanisms of virologic failure in previously untreated HIV-infected patients from a trial of induction-maintenance therapy. J. Am. Med. Assoc. 283, 205-211.
9. Eldred L., and Cheever L. Update on adherence to HIV therapy. Hopkins HIV Rep. 10 1 (1998) 10-11
10. Ferguson N.M., Donnelly C.A., Hooper J., Ghani A.C., Fraser C., Bartley L.M., Rode R.A., Vernazza P., Lapins D., Mayer S.L., and Anderson R.M. Adherence to antiretroviral therapy and its impact on clinical outcome in HIV-infected patients. J. R. Soc. Interface 2 4 (2005) 349-363
11. Giordano T.P., Guzman D., Clark R., Charlebois E.D., and Bangsberg D.R. Measuring adherence to antiretroviral therapy in a diverse population using a visual analogue scale. HIV Clinical Trials 5 2 (2004) 74-79
12. Grabar S., Pradier C., Le Corfec E., Lancar R., Allavena C., Bentata M., Berlureau P., Dupont C., Fabbro-Peray P., Poizot-Martin I., and Costagliola D. Factors associated with clinical and virological failure in patients receiving a triple therapy including a protease inhibitor. AIDS 14 2 (2000) 141-149
13. Gross R., Bilker W.B., Friedman H.M., and Strom B.L. Effect of adherence to newly initiated antiretroviral therapy on plasma viral load. AIDS 15 16 (2001) 2109-2117
14. Harrigan P.R., Hogg R.S., Dong W.W., Yip B., Wynhoven B., Woodward J., Brumme C.J., Brumme Z.L., Mo T., Alexander C.S., and Montaner J.S. Predictors of HIV drug-resistance mutations in a large antiretroviral-naive cohort initiating triple antiretroviral therapy. J. Infect. Dis. 191 3 (2005) 339-347
15. Heffernan J.M., and Wahl L.M. Natural variation in HIV infection: Monte Carlo estimates that include CD8 effector cells. J. Theor. Biol. 243 (2006) 191-204
16. Hinkin C.H., Hardy D.J., Mason K.I., Castellon S.A., Durvasula R.S., Lam M.N., and Stefaniak M. Medication adherence in HIV-infected adults: effect of patient age, cognitive status, and substance abuse. AIDS 18 Suppl. 1 (2004) S19-S25
17. Howard A.A., Arnsten J.H., Lo Y., Vlahov D., Rich J.D., Schuman P., Stone V.E., Smith D.K.f., and Schoenbaum E.E.f.t.H.S.G. A prospective study of adherence and viral load in a large multi-center cohort of HIV-infected women. AIDS 16 16 (2002) 2175-2182
18. Huang Y., Rosenkranz S.L., and Wu H. Modeling HIV dynamics and antiviral response with consideration of time-varying drug exposures, adherence and phenotypic sensitivity. Math. Biosci. 184 2 (2003) 165-186
19. Karlin S., and Taylor H.M. A First Course in Stochastic Processes (1975), Academic Press, New York
20. Kathleen J.R. Barriers to and facilitators of HIV-positive patients' adherence to antiretroviral treatment regimens. AIDS Patient Care STDs 14 3 (2000) 155-168
21. Krakovska, O., Wahl, L.M., 2007. Costs versus benefits: best possible and best practical treatment regimens for HIV. J. Math. Biol., in press, doi:10.1007/s00285-006-0059-1.
22. Lohse N., Obel N., Kronborg G., Laursen A., Pedersen C., Larsen C.S., Kvinesdal B., Sorensen H.T., and Gerstoft J. Declining risk of triple-class antiretroviral drug failure in Danish HIV-infected individuals. AIDS 19 8 (2005) 815-822
23. Maitland D., Moyle G., Hand J., Mandalia S., Boffito M., M N., and Gazzard B. Early virologic failure in HIV-1 infected subjects on didanosine/tenofovir/efavirenz: 12-week results from a randomized trial. AIDS 19 11 (2005) 1183-1188
24. Martin-Carbonero L., Soriano V., Valencia E., Garcia-Samaniego J., Lopez M., and Gonzalez-Lahoz J. Increasing impact of chronic viral hepatitis on hospital admissions and mortality among HIV-infected patients. AIDS Res. Hum. Retroviruses 17 16 (2001) 1467-1471
25. Martinez-Picado J., Negredo E., Ruiz L., Shintani A., Fumaz C.R., Zala C., Domingo P., Vilaro J., Llibre J.M., Viciana P., Hertogs K., Boucher C., D'Aquila R.T., Clotet B., and SWATCH Study Team. Alternation of antiretroviral drug regimens for HIV infection. A randomized, controlled trial. Ann. Intern. Med. 139 2 (2003) 81-89
26. Mocroft A., Ledergerber B., Viard J.P., Staszewski S., Murphy M., Chiesi A., Horban A., Hansen A.B., Phillips A.N., Lundgren J.D., and EuroSIDA Study Group. Time to virological failure of 3 classes of antiretrovirals after initiation of highly active antiretroviral therapy: results from the EuroSIDA Study Group. J. Infect. Dis. 190 11 (2004) 1947-1956
27. Montaner J., Hill A., and Acosta E. Practical implications for the interpretation of minimum plasma concentration/inhibitory concentration ratios. Lancet 357 9266 (2001) 1438-1440
28. Montaner J.S., Reiss P., Cooper D., Vella S., Harris M., Conway B., Wainberg M.A., Smith D., Robinson P., Hall D., Myers M., and Lange J.M. A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS trial. J. Am. Med. Assoc. 279 12 (1998) 930-937
29. Oyugi J.H., Byakika-Tusiime J.B., Charlebois E.D., Kityo C., Mugerwa R., Mugyenyi P., and Bangsberg D.R. Multiple validated measures of adherence indicate high levels of adherence to generic HIV antiretroviral therapy in a resource-limited setting. JAIDS 36 5 (2004) 1100-1102
30. Paterson D.L., Swindells S., Mohr J., Brester M., Vergis E.N., Squier C., Wagener M.M., and Singh N. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann. Intern. Med. 133 1 (2000) 21-30
31. Phillips, A.N., Staszewski, S., Weber, R., Kirk, O., Francioli, P., Miller, V., Vernazza, P., Lundgren, J.D., Ledergerber, B., Swiss HIV Cohort Study, Frankfurt HIV Clinic Cohort, and EuroSIDA Study Group, 2001a. HIV viral load response to antiretroviral therapy according to the baseline CD4 cell count and viral load. J. Am. Med. Assoc. 286(20), 2560-2567.
32. Phillips A.N., Youle M., Johnson M., and Loveday C. Use of a stochastic model to develop understanding of the impact of different patterns of antiretroviral drug use on resistance development. AIDS 15 17 (2001) 2211-2220
33. Phillips, A.N., Dunn, D., Sabin, C., Pozniak, A., Matthias, R., Geretti, A.M., Clarke, J., Churchill, D., Williams, I., Hill, T., Green, H., Porter, K., Scullard, G., Johnson, M., Easterbrook, P., Gilson, R., Fisher, M., Loveday, C., Gazzard, B., Pillay, D., UK Collaborative Group on HIV Drug Resistance, and UK CHIC Study Group, 2005. Long term probability of detection of HIV-1 drug resistance after starting antiretroviral therapy in routine clinical practice. AIDS 19(5), 487-494.
34. Roca B., Gomez C.J., and Arnedo A. Adherence, side effects and efficacy of stavudine plus lamivudine plus nelfinavir in treatment-experienced HIV-infected patients. J. Infect. 41 1 (2000) 50-54
35. Sethi, A.K., Celentano, D.D., Gange, S.J., Moore, R.D., Gallant, J.E., 2003. Association between adherence to antiretroviral therapy and human immunodeficiency virus drug resistance. Clin. Infect. Dis. 37 (8), 1112-1118.
36. Siegel K., Schrimshaw E.W., and Raveis V.H. Accounts for non-adherence to antiviral combination therapies among older HIV-infected adults. Psychol. Health Med. 5 1 (2000) 29-42
37. Smith R.J. Adherence to antiretroviral HIV drugs: how many doses can you miss before resistance emerges?. Proc. R. Soc. London B Biol. Sci. 273 1586 (2006) 617-624
38. Smith R.J., and Wahl L.M. Distinct effects of protease and reverse transcriptase inhibition in an immunological model of HIV-1 infection with impulsive drug effects. Bull. Math. Biol. 66 5 (2004) 1259-1283
39. Smith R.J., and Wahl L.M. Drug resistance in an immunological model of HIV-1 infection with impulsive drug effects. Bull. Math. Biol. 67 4 (2005) 783-813
40. Verotta D., and Schaedeli F. Non-linear dynamics models characterizing long-term virological data from AIDS clinical trials. Math. Biosci. 176 2 (2002) 163-183
41. Wahl L.M., and Nowak M.A. Adherence and resistance: predictions for therapy outcome. Proc. Biol. Sci. 267 1445 (2000) 835-843
42. Walsh J.C., Pozniak A.L., Nelson M.R., Mandalia S., and Gazzard B.G. Virologic rebound on HAART in the context of low treatment adherence is associated with a low prevalence of antiretroviral drug resistance. J. Acquir. Immune Defic. Syndr. 30 3 (2002) 278-287
43. Weiser S., Wolfe W., Bangsberg D., Thior I., Gilbert P., Makhema J., Kebaabetswe P., Dickenson D., Mompati K., Essex M., and Marlink R. Barriers to antiretroviral adherence for patients living with HIV infection and AIDS in Botswana. JAIDS 34 3 (2003) 281-288
44. + cell count is 0.200 to 0.350 × 10 (9) cells / L. Ann. Intern. Med. 139 10 (2003) 810-816
45. Wu H., Huang Y., Acosta E.P., Rosenkranz S.L., Kuritzkes D.R., Eron J.J., Perelson A.S., and Gerber J.G. Modeling long-term HIV dynamics and antiretroviral response: effects of drug potency, pharmacokinetics, adherence, and drug resistance. J. Acquir. Immune Defic. Syndr. 39 3 (2005) 272-283